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Original article
The efficacy of statin therapy in lowering the risk of car-
diovascular events and death in secondary prevention of 
cardiovascular disease (CVD) is well accepted.1,2 Several 
studies also support the use of statins for primary preven-
tion among individuals at high risk for CVD.3,4 The health 
benefits of statin therapy are largely attributed to the lipid-
lowering characteristics of statins.5 However, pleiotropic 
properties such as favorable effects on their interaction 
with the renin-angiotensin system,6 endothelial function,7 
and arterial compliance8 have also been suggested. In 
addition, recent studies,9,10 including two meta-analyses 
of randomized controlled trials,5,11 demonstrated a small 
but clinically relevant reductions in systolic blood pressure 
(BP) attributable to statin therapy. This evidence, along 
with the likely coexistence of hypertension and hypercho-
lesterolemia,12 makes the combination of antihypertensive 
medication and statins a common course of therapy in 
such individuals.
Statin Therapy, Fitness, and Mortality Risk in Middle-Aged 
Hypertensive Male Veterans
Peter Kokkinos,1–3 Charles Faselis,4,5 Jonathan Myers,6,7 John Peter Kokkinos,4 Michael Doumas,4,5 
Andreas Pittaras,4,5 Raya Kheirbek,4,5 Athanasios Manolis,8,9 Demosthenes Panagiotakos,10 
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background
Hypertension often coexists with dyslipidemia, accentuating cardio-
vascular risk. Statins are often prescribed in hypertensive individuals 
to lower cardiovascular risk. Higher fitness is associated with lower 
mortality, but exercise capacity may be attenuated in hypertension. 
The combined effects of fitness and statin therapy in hypertensive 
individuals have not been assessed. Thus, we assessed the combined 
health benefits of fitness and statin therapy in hypertensive male 
subjects.
methods
Peak exercise capacity was assessed in 10,202 hypertensive male 
subjects (mean age  =  60.4 ± 10.6  years) in 2 Veterans Affairs Medical 
Centers. We established 4 fitness categories based on peak metabolic 
equivalents (METs) achieved and 8 categories based on fitness status 
and statin therapy.
results
During the follow-up period (median  =  10.2  years), there were 2,991 
deaths. Mortality risk was 34% lower (hazard ratio (HR)  =  0.66; 95% 
confidence interval (CI)  =  0.59–0.74; P  <  0.001) among individuals 
treated with statins compared with those not on statins. The fitness-
related mortality risk association was inverse and graded regardless 
of statin therapy status. Risk reduction associated with exercise capac-
ity of 5.1–8.4 METs was similar to that observed with statin therapy. 
However, those achieving ≥8.5 METs had 52% lower risk (HR = 0.48; 95% 
CI = 0.37–0.63) when compared with the least-fit subjects (≤5 METs) on 
statin therapy.
conclusions
The combination of statin therapy and higher fitness lowered mortality 
risk in hypertensive individuals more effectively than either alone. The 
risk reduction associated with moderate increases in fitness was similar 
to that achieved by statin therapy. Higher fitness was associated with 
52% lower mortality risk when compared with the least fit subjects on 
statin therapy.
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Strong epidemiologic evidence supports an inverse and 
graded association between increased exercise capacity and 
mortality in hypertensive individuals regardless of addi-
tional comorbidities.13–17 Increased physical activity leading 
to improved fitness status is now recommended for hyper-
tensive individuals as an adjunct to antihypertensive medi-
cation to manage BP and lower mortality risk.18,19 We have 
also reported that higher fitness and statin therapy work syn-
ergistically to lower mortality risk more than either therapy 
alone in dyslipidemic individuals.20 However, muscle dam-
age,21 mitochondrial dysfunction,22attenuated cardiorespi-
ratory fitness,23 and other maladaptive changes that could 
negatively impact exercise and lifestyle-related health ben-
efits24 have been reported recently with the use of statins. In 
addition, some studies have shown that exercise capacity is 
attenuated in hypertensive individuals.25,26
Thus, it is not known whether the health benefits of exercise 
are attenuated by statin therapy or whether the 2 therapeutic 
strategies act synergistically to result in better outcomes than 
either therapy alone for hypertensive individuals. Therefore, 
the aim of this study was to assess the independent and com-
bined effects of statin therapy and fitness status on mortality 
risk in individuals with established hypertension.
METHODS
Study design and sample
This prospective cohort study consisted of 10,202 hyper-
tensive male veterans from the Veterans Affairs Medical 
Centers in Washington, DC, and Palo Alto, California. Of 
those, 5,947 were black (mean age  =  58.9 ± 10.7  years), 
3,776 were white (mean age  =  62.4 ± 10.3  years), and 479 
were other races (i.e., Native Americans and Asians; mean 
age = 62.3 ± 10.2 years). The cohort reflects individuals from 
a larger database (>20,000), identified with hypertension 
defined by International Classification of Diseases coding, 
who underwent a symptom-limited exercise tolerance test 
between 1986 and 2011. The exercise tolerance test was 
administered either as part of a routine evaluation or to 
assess exercise-induced ischemia. This information, along 
with the individual’s medical history, was electronically 
stored.
Individuals with any of the following characteristics were 
excluded: (i) history of an implanted pacemaker; (ii) devel-
opment of left bundle branch block during the test; (iii) 
inability to complete the test because of musculoskeletal 
pain or impairments; (iv) an exercise capacity <2 metabolic 
equivalents (METs); (v) instability or requirement of emer-
gent intervention; (vi) body mass index (BMI) <15.5 kg/m2; 
and (vii) an impaired chronotropic response to exercise.
The study was approved by the institutional review board 
at each institution, and all subjects gave written informed 
consent before undergoing the exercise tolerance test.
Measurements
Demographic information, clinical characteristics, and med-
ication information (Table 1) were obtained from the subject’s 
electronic medical record just before his exercise tolerance test. 
Each individual was asked to verify the computerized informa-
tion, including history of chronic disease, current medications, 
and smoking habits. Body weight and height were assessed by 
a standardized scale and recorded before the test. BMI was cal-
culated as weight (kg) divided by height squared (m2).
The duration of statin therapy was based on the initial and 
last date statins were prescribed for each patient. Individuals 
were considered to be on statin therapy if these 2 dates were 
>3  months apart. Lipid and lipoprotein evaluations reflect 
the most recent values in the record (Table 1).
Exercise assessments
Exercise capacity was assessed by a standard treadmill test 
using the Bruce protocol at the Veterans Affair Medical Center 
in Washington, DC, and an individualized ramp protocol as 
described elsewhere27,28 for subjects assessed at the Veterans 
Affair Medical Center in Palo Alto, California. Peak exercise 
time was recorded in minutes. Peak exercise capacity (METS) 
was estimated using standardized equations based on peak 
speed and grade for the ramp protocol28 and on peak exer-
cise time for the Bruce protocol.27 One MET is defined as the 
energy expended at rest, which is approximately equivalent to 
an oxygen consumption of 3.5 ml per kg of body weight per 
minute. Subjects were encouraged to exercise until volitional 
fatigue in the absence of symptoms or other indications for 
stopping.29 The use of handrails was allowed only if neces-
sary for balance and safety. Age-predicted peak exercise heart 
rate was determined using a population-specific equation.28 
Medications were not altered before testing.
Four fitness categories were formed (quartiles) based on 
the peak MET level achieved. Those who achieved a peak 
level ≤5 METs (lowest 25th percentile of the MET level 
achieved by the cohort) comprised the lowest fitness cate-
gory (least fit; n = 2,674); those with a peak MET level of 5.1–
6.5 (26th to 50th percentile) comprised the low fit category 
(low fit; n = 2,489); those with a peak MET level of 6.6–8.4 
(51st to 75th percentile) comprised the fit category (mod-
erate fit; n = 3,338), and those with a peak MET level ≥8.5 
(>75th percentile), comprised the highest fit category (high 
fit; n  =  1,701). To further explore the combined effects of 
fitness and statin therapy on mortality, we formed 2 groups 
(treated with statin and not treated with statin) within each 
fitness category for a total of 8 fitness/statin categories.
Follow-up and endpoint
The endpoint studied was death from any cause. Dates of 
death were verified from the Veterans Affairs Beneficiary 
Identification and the Record Locator System File. This sys-
tem is used to determine benefits to survivors of veterans 
and has been shown to be 95% complete and accurate.30 
Vital status was determined as of December 2011. No miss-
ing cases existed in the sample in terms of vital information.
Statistical analysis
Follow-up time is presented as median, 25th, and 75th per-
centiles. Mortality rate was calculated as the ratio of events 
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presented as mean values and SD, and categorical variables 
are presented as relative frequencies (%). Baseline associa-
tions between categorical variables were tested using χ2 tests. 
One-way analysis of variance and t tests were applied to eval-
uate mean differences of selected variables between individ-
uals on and not on statin therapy. The assumption of equality 
of variances between groups was tested by Levene’s test, and 
the assumption of normality was evaluated using p-p plots. 
Hazard ratios (HRs) for all-cause mortality were calculated 
for the 4 fitness categories, the 2 statin categories (statin/no 
statin), and the 8 fitness/statin categories using Cox propor-
tional hazards models. First-order interactions between sta-
tin treatment and fitness groups were also evaluated.
For the 4 fitness categories, individuals in the least-fit cat-
egory (≤5 METs) comprised the reference group. For the 
statin/no statin categories, individuals not on statin therapy 
comprised the reference group. In the fully adjusted model, 
we adjusted for age, BMI, ethnicity, CVD, risk factors (type 2 




No. 10,202 4,529 5,673
Age, y 60.4 ± 11 59.7 ± 10 60.9 ± 11 <0.01
Weight, kg 91.6 ± 18.2 93.6 ± 17.9 90 ± 18.2 <0.01
BMI, kg/m2 29.5 ± 5.6 30.1 ± 5.4 29.0 ± 5.7 <0.01
Resting heart rate, beats/min 73 ± 14 72 ± 13 74 ± 14 0.76
Resting systolic BP, mm Hg 135 ± 21 132 ± 18 138 ± 22 <0.01
Resting diastolic BP, mm Hg 81 ± 12 79 ± 12 82 ± 12 <0.01
Peak MET 6.6 ± 2.0 6.9 ± 2.0 6.3 ± 1.9 <0.01
Total cholesterol, mg/dl 189 ± 45 179 ± 44 198 ± 44 <0.01
LDL cholesterol, mg/dl 127 ± 47 114 ± 42 142 ± 47 <0.01
HDL cholesterol, mg/dl 43 ± 12 43 ± 12 44 ± 12 0.05
Triglycerides, mg/dl 144 ± 91 146 ± 95 139 ± 80 0.22
Race
 Black 58.3 n = 5,947 67.1 n = 3,037 51.3 n = 2,910 <0.01
 White 37 n = 3,776 30.2 n = 1,363 42.5 n = 1,624 <0.01
 Others 4.7 n = 479 26.1 n = 125 6.2 n = 354 <0.01
History of CVD 36.5 n = 3,726 50.6 n = 1,885 35 n = 1,841 <0.01
Dyslipidemia 54.1 n = 5,520 86.7 n = 3,927 28.1 n = 1,593 <0.01
Smoking 31.7 n = 3,237 33.3 n = 1,510 30.4 n = 1,727 <0.01
Type 2 diabetes mellitus 49.2 n = 5,017 57 n = 2,580 43 n = 2,437 <0.01
Insulin 1,237 (12.1) 1,029 (22.7) 208 (3.7) <0.01
Oral hypoglycemic agents 1,905 (18.5) 1,585 (35) 320 (5.6) <0.01
Cardiac medication
 Beta-blocker 20.2 n = 2,060 22.5 n = 1,021 18.3 n = 1,039 <0.01
 CCB 24.7 n = 2,517 23.6 n = 1,067 25.6 n = 1,450 <0.01
 ACE/ARB 27.2 n = 2,770 35.7 n = 1,616 20.3 n = 1,154 <0.01
 Diuretics 16.6 n = 943 27.6 n = 1,250 5 n = 246 <0.01
 Nitrates/vasodilators 7.1 n = 728 4.1 n = 184 9.6 n = 544 <0.01
 Antiarrhythmic agents 2.4 n = 247 4.5 n = 202 0.8 n = 45 <0.01
 Drug/alcohol abuse 7.4 n = 750 9.4 n = 424 5.7 n = 5.7 <0.01
 MWD 16 n = 1,630 20.8 n = 940 12.2 n = 690 <0.01
Data are mean ± SD or percentage. P values derived using χ2 test for medication and medical history between statin treatment groups and 
using t test for the rest of variables.
Abbreviations: ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pres-
sure; CCB, calcium channel blocker; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-densiety lipoprotein; MET, metabolic 
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diabetes mellitus, dyslipidemia, and smoking), muscle-wast-
ing diseases (MWD) (cancer, HIV/AIDS, and renal failure), 
sleep apnea, cardiac medications (beta-blockers, calcium-
channel blockers, diuretics, angiotensin-converting enzyme 
inhibitors, angiotensin II receptor blockers, antiarrhythmic 
agents), insulin, oral hypoglycemic agents, and lipid-lower-
ing (nonstatins) agents. All variables included in the mod-
els were based on the rationale of their clinical role on the 
outcome and the main factors of interest. Cox proportional 
hazards models were also used to assess risk among the 8 fit-
ness/statin categories. The model was adjusted for the afore-
mentioned covariables according to the rationale mentioned. 
For the latter analysis, the least-fit individuals not on statin 
therapy (least fit/no statins) comprised the reference group. 
We also performed a subgroup analysis (n = 4,848) to directly 
assess mortality risk between the least-fit individuals treated 
with statins (referent) and individuals in the remaining fit-
ness categories (low, moderate, and high fit) not treated with 
statins. The assumption of proportionality for all Cox pro-
portional hazard analyses was graphically tested by plotting 
the cumulative hazards of the logarithms of the covariables; 
the proportionality assumption was fulfilled for each model. 
All hypotheses were 2-sided, and P values <0.05 were consid-
ered statistically significant. All statistical analyses were per-
formed using SPSS software version 19.0 (SPSS, Chicago, IL).
RESULTS
The median follow-up period was 10.2 years (25th and 
75th percentiles = 5.7 and 14.5, respectively), comprising 
a total of 107,620 person-years. There were 2,991 deaths 
(29.3% overall mortality in the cohort), with an average 
annual mortality of 27.8 events per 1,000 person-years 
of observation. Significantly higher mortality rates were 
noted for individuals not treated with statins (35.5% vs. 
26.2%; P < 0.01) and those with CVD (40.7% vs. 21.9%), 
MWD (47.5% vs. 25.9%; P < 0.01), and smokers (31.4% 
vs. 28.1%; P  <  0.01). Those who died were also older 
(64.8 ± 10 vs. 58.6 ± 10  years; P  <  0.01) and had higher 
systolic BP (142 ± 23 vs. 133 ± 20 mm Hg; P  <  0.01) and 
lower exercise capacity (5.6 ± 1.7 vs. 7.0 ± 2.0 METs; 
P < 0.01). There was no interaction between site-by-METs 
(P = 0.23) or race-by-METs (P = 0.06), and therefore the 
data were not stratified by site or race. However, there was 
an interaction between fitness categories and statin use 
(P = 0.01) as well as statin use and peak METs achieved 
(P < 0.01).
Demographic and clinical characteristics for the entire 
cohort and the 2 statin categories are presented in Table  1. 
Individuals on statin therapy were slightly younger and had 
higher BMI and exercise capacity and lower systolic and dias-
tolic BP when compared with those not on statin therapy. The 
prevalence of CVD, smoking, dyslipidemia, type 2 diabetes 
mellitus, drug/alcohol abuse, MWD, and the use of beta-block-
ers, angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, antiarrhythmic agents, diuretics, insulin, 
and oral hypoglycemic agents were also higher in those on 
statin therapy. The use of nitrates/vasodilators and calcium 
channel blockers were higher in those not on statin therapy. 
The median duration of statin therapy was 77.6  months. 
Approximately 98% of the individuals in the statin group were 
treated with statins for at least 12 months, and only 186 indi-
viduals (approximately 1.8%) were treated for <12 months.
Significantly more favorable lipid profiles were noted in 
total cholesterol and low density lipoprotein (LDL) choles-
terol among those on statin therapy (Table 1).
Predictors of mortality risk for the entire cohort and 
according to statin or no statin therapy
In the fully adjusted model, significant predictors for 
increased all-cause mortality were age (HR  =  1.03; 95% 
confidence interval (CI)  =  1.02–1.04; P  <  0.01), systolic BP 
(HR  =  1.006; 95% CI  =  1.004–1.008; P  <  0.01), smoking 
(HR = 1.30; 95% CI = 1.20–1.40; P < 0.01); type 2 diabetes 
(HR = 1.43; 95% CI = 1.32–1.56; P < 0.01); CVD (HR = 1.28; 
95% CI  =  1.18–1.38; P  <  0.01), MWD (HR  =  1.82; 95% 
CI = 1.66–1.98; P < 0.01) and drug/alcohol abuse (HR = 1.29; 
95% CI  =  1.11–1.50; P  <  0.01). Conversely, lower mortality 
risk was observed with BMI (HR  =  0.98; 95% CI  =  0.97–
0.99; P < 0.01), use of hypoglycemic agents (HR = 0.74; 95% 
CI = 0.65–0.83; P < 0.01), antihypertensive/cardiac medica-
tion (HR = 0.74; 95% CI = 0.67–0.81; P < 0.01), statin therapy 
(HR = 0.66; 95% CI: 0.59-0.74; P < 0.001), and exercise capac-
ity. For every 1-MET increase in exercise capacity, the adjusted 
mortality for the entire cohort was 15% lower (HR = 0.85; 95% 
CI = 0.83–0.87; P < 0.01). The influence of exercise capacity 
was substantially more potent in the statin therapy group. 
For every 1-MET increase in exercise capacity, the adjusted 
mortality risk was 19% lower per MET achieved (HR = 0.81; 
95% CI = 0.78–0.85; P < 0.01) and 14% for those not treated 
with statins (HR = 0.86; 95% CI = 0.84–0.88; P < 0.01). The 
adjusted mortality risk was significantly lower (34%) for those 
on statin therapy compared with those not on statin therapy 
(HR = 0.66; 95% CI = 0.59–0.74; P < 0.01).
Mortality risk according to fitness categories and statin 
therapy
HRs across fitness categories for the entire cohort and 
for the statin and no statin therapy groups are presented in 
Table 2 and illustrated in Figure 1a–c. The partially and fully 
adjusted mortality risks for the 4 fitness categories are shown, 
with those in the least-fit category (≤5 METs) as the refer-
ence group. For the entire cohort in the fully adjusted model 
(Table 2), the mortality risk was progressively lower as exer-
cise capacity increased, such that individuals with an exercise 
capacity >5 METs had 27%–69% reductions in risk (P < 0.01). 
Similarly, the fully adjusted risks for individuals treated with 
statins were progressively lower with increased exercise capac-
ity, ranging 31%–75% for individuals on statin therapy and 
24%–64% for those not treated with statins (Table 2).
We also examined the mortality risk according to fitness 
for individuals with documented CVD and those without 
CVD (Table 3). In both subgroups, the association between 
fitness categories and mortality risk was inverse and graded. 
However, mortality rates for individuals with CVD were 
substantially higher within each fitness category and the 
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Because there was a significant interaction between fitness 
categories and statin use, we sought to explore further the 
combined effect of fitness and statins. For this, we performed 
additional analyses to assess possible differences in mor-
tality risk between those on statin therapy compared with 
those not on statin therapy. We used the least-fit individu-
als not treated with statins (least fit/no statins) as the refer-
ence group. The model was adjusted for age, BMI, ethnicity, 
CVD, risk factors, MWD, sleep apnea, cardiac medications, 
insulin, oral hypoglycemic agents, and lipid-lowering (non-
statins) agents. In the fully adjusted model, the association 
between fitness and mortality risk was inverse and graded for 
subjects both treated and not treated with statins. However, 
the combination of statins and higher fitness was substan-
tially more effective in lowering mortality risk than either 
treatment alone.
It was also noteworthy that the risk for individuals in the 
high-fit/no statins category was similar to that in the moder-
ate-fit/statins category (HR = 0.37 vs. 0.35, respectively) and 
substantially lower than the risk observed for those in the 
low-fit and least-fit categories on statin therapy (Table 4). To 
directly compare mortality risks associated with fitness vs. 
statin therapy, we performed a subgroup analysis (n = 4,848) 
comparing the least-fit individuals treated with statins (ref-
erent) to individuals in the low, moderate, and high fitness 
categories not treated with statins. The findings revealed 
similar mortality risks for low-fit subjects (HR = 0.99; 95% 
CI = 0.83–1.17; P = 0.91). However, the risk was 24% lower 
for moderate-fit subjects (HR = 0.76; 95% CI = 0.64–0.91; 
P < 0.01) and 52% lower for individuals in the high-fit cat-
egory (HR = 0.48; 95% CI = 0.37–0.63; P < 0.01) (Figure 2).
DiSCUSSiON
The findings of this study support the concept that both 
statin therapy and higher fitness lower mortality risk in 
hypertensive individuals, independently and synergisti-
cally. More specifically, the overall risk reduction related 
to statin therapy was 34%. The fitness-related reduction in 
mortality risk was inverse and graded. Relative to individu-
als with an exercise capacity ≤5 METs, mortality risk was 
27%, 43%, and 69% lower for the moderate-fit, fit and high-
fit individuals, respectively (Table 2). The trend was similar 
for those treated and not treated with statins (Table  2). As 
illustrated in Figure 1b, approximately 90% of the individu-
als in the high-fit category on statin therapy were still alive at 
15 years of follow-up compared with approximately 80% of 
those within the same fitness category not treated with statins 
(Figure 1c). Similarly, for individuals in the least-fit category 
treated with statins, approximately 65% were still alive at 
15 years compared with approximately 55% for those in the 
same fitness category not treated with statins. These findings 
are in accord with previous reports regarding statin therapy 
in primary or secondary prevention of mortality in individu-
als at high CVD risk.1–4 The inverse and graded association 
between fitness and mortality risk in hypertensive individu-
als has also been described previously.13–15,17 We have also 
reported on the combined effects of statin therapy and fitness 
in dyslipidemic individuals.20 Because approximately 54% 
of our cohort in this study was dyslipidemic, some overlap-
ping exists between the cohort of this study and our previous 
work.20 However, given the likely coexistence of hypertension 
and dyslipidemia12 and the use of statins in combination with 
Table 2. Hazards ratios for mortality risk of the entire cohort and according to statin therapy
Fitness categories according  
to peak METs achieved No. of deaths (%)
Hazard ratio, age- 
adjusted (95% CI)
Hazard ratio, adjusted for age 
and resting BP (95% CI)
Hazard ratio, fully 
adjusted (95% CI) P value
Entire cohort (n = 10,202)
 ≤5 MET (n = 2,674) 531 (51.0) 1.00 (referent) 1.00 (referent) 1.00 (referent) —
 5.1–6.5 MET (n = 2,489) 397 (32.1) 0.68 (0.63–0.75) 0.69 (0.63–0.75) 0.73 (0.67–0.80) <0.01
 6.6–8.4 MET (n = 3,338) 270 (20.5) 0.49 (0.44–0.54) 0.50 (0.45–0.55) 0.56 (0.51–0.62) <0.01
 ≥8.5 MET (n = 1,701) 190 (8.5) 0.25 (0.21–0.30) 0.26 (0.22–0.31) 0.31 (0.26–0.38) <0.01
Individuals on statin therapy (n = 4,529)
 ≤5 MET (n = 923) 345 (37.4) 1.00 (referent) 1.00 (referent) 1.00 (referent) —
 5.1–6.5 MET (n = 1,146) 252 (22.0) 0.63 (0.54–0.74) 0.64 (0.55–0.76) 0.68 (0.58–0.80) <0.01
 6.6–8.4 MET (n = 1,510) 180 (11.9) 0.42 (0.34–0.50) 0.43 (0.36–0.52) 0.46 (0.38–0.56) <0.01
 ≥8.5 MET (n = 950) 51 (5.4) 0.22 (0.16–0.30) 0.23 (0.17–0.31) 0.25 (0.19–0.34) <0.01
Individuals not on statin therapy (n = 5,673)
 ≤5 MET (n = 1,751) 1,018 (58.1) 1.00 (referent) 1.00 (referent) 1.00 (referent) —
 5.1–6.5 MET (n = 1,343) 548 (40.8) 0.73 (0.66–0.81) 0.73 (0.66–0.82) 0.76 (0.68–0.84) <0.01
 6.6–8.4 MET (n = 1,828) 504 (27.6) 0.53 (0.48–0.60) 0.54 (0.48–0.61) 0.60 (0.54–0.67) <0.01
 ≥8.5 MET (n = 751) 93 (12.4) 0.32 (0.25–0.40) 0.32 (0.26–0.40) 0.36 (0.29–0.46) <0.01
Abbreviations: BP, blood pressure; CI, confidence interval; MET, metabolic equivalent; MWD, muscle-wasting disease.
The model was adjusted for age, resting blood pressure, body mass index, ethnicity, beta-blockers, calcium channel blockers, angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, antiarrhythmic agents, insulin, oral hypoglycemic agents, history of 
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Figure 1. Mortality risk in hypertensive individuals. (a) Mortality risk in hypertensive individuals according to fitness categories. (b) Mortality risk in 
hypertensive individuals on statin therapy according to fitness categories on statin therapy. (c) Mortality risk in hypertensive individuals on statin therapy 
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antihypertensive medication in such individuals, the com-
bined effects of fitness and statins in hypertensive individuals 
merits special consideration. Therefore, these findings add to 
the expanding body of information on this issue.
Our findings suggest that higher fitness combined with 
statin therapy was the most effective approach in lowering 
mortality risk in hypertensive individuals. More specifically, 
the mortality risks for least-fit (≤5 METs), low-fit (5.1–6.5 
METs), moderate-fit (6.6–8.4 METs), and high-fit individu-
als (≥8.5 METs) on statin therapy were 25%, 49%, 65%, and 
82% lower, respectively, when compared with the least-fit 
individuals not treated with statins (Table 4). It is also note-
worthy that low-, moderate-, and high-fit individuals not 
treated with statins exhibited 24%, 40%, and 63% lower mor-
tality risk, respectively (Table  4). This suggests that higher 
fitness may be at least as effective as statin therapy in low-
ering mortality risk in hypertensive individuals. To further 
assess this, we performed a subgroup analysis (n  =  4,848) 
comparing the least-fit individuals on statin therapy (ref-
erence group) to the individuals in the remaining fitness 
categories not treated with statins. This analysis revealed 
similar risk for the low-fit individuals. However, mortality 
risk for moderate-fit and high-fit individuals was 24% and 
52% lower compared with the least-fit individuals on statin 
therapy (P < 0.01) (Figure 2).
These findings are clinically relevant because a substantial 
number of individuals may not tolerate statins. For individu-
als who cannot tolerated statin therapy for various reasons, a 
relatively moderate increase in fitness may provide an alter-
native and effective way to lower mortality risk. The exer-
cise capacity >5 METs that was associated with similar risk 
reduction to that provided by statin therapy is easily achiev-
able by most middle-aged or older individuals. Thus, these 
findings lead to the salient concept that physical activity is 
an efficacious and cost-effective way to prevent premature 
mortality in hypertensive individuals and therefore should 
be promoted by health-care providers.
Several other aspects of this study are noteworthy. This is 
the only evaluation to our knowledge to assess the association 
between the combination of statin therapy and fitness for the 
treatment of hypertensive individuals. The statin–fitness–
mortality association was assessed in the largest clinically 
referred cohort of hypertensive individuals (n  =  10,202), 
>58% of whom were black, with a follow-up time of 107,620 
person-years. Despite recent reports of unfavorable effects 
of statin therapy on cardiorespiratory fitness,23 exercise 
Table 4. Hazards ratios for mortality risk for the combined fitness and statin categories
Groups No. of Deaths (%)
Hazard ratio, age- 
adjusted (95% CI)
Hazard ratio, adjusted for 
age and resting BP (95% CI)
Hazard ratio, fully 
adjusted (95% CI) P value
Least fit/no statins (n = 1,748) 1,017 (58.2) 1.00 (referent) 1.00 (referent) 1.00 (referent) —
Least fit/statins (n = 923) 345 (37.4) 0.70 (0.62–0.79) 0.70 (0.66–0.82) 0.75 (0.65–0.87) <0.01
Low fit/no statins (n = 1,346) 549 (40.8) 0.73 (0.66–0.82) 0.74 (0.66–0.82) 0.76 (0.68–0.84) <0.01
Low fit/statins (n = 1,146) 252 (22) 0.45 (0.39–0.52) 0.46 (0.40–0.53) 0.51 (0.44–0.60) <0.01
Moderate fit/no statins (n = 1,830) 504 (27.2) 0.54 (0.48–0.60) 0.54 (0.49–0.61) 0.60 (0.53–0.67) <0.01
Moderate fit/statins (n = 1,511) 180 (11.7) 0.29 (0.24–0.34) 0.29 (0.25–0.35) 0.35 (0.29–0.42) <0.01
High fit/no statins (n = 749) 93 (12.4) 0.33 (0.26–0.40) 0.33 (0.27–0.41) 0.37 (0.30–0.46) <0.01
High fit/statins (n = 949) 51 (5.4) 0.15 (0.11–0.19) 0.15 (0.11–0.20) 0.18 (0.13–0.25) <0.01
Abbreviations: BP, blood pressure; CI, confidence interval; MET, metabolic equivalent; MWD, muscle-wasting disease.
The model was adjusted for age, resting blood pressure, body mass index, ethnicity, beta-blockers, calcium channel blockers, angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, antiarrhythmic agents, insulin, oral hypoglycemic agents, history of 
smoking, cardiovascular disease, dyslipidemia, MWD, sleep apnea, alcohol/drug abuse, diabetes mellitus, and year of entry in the study.
Table 3. Hazards ratios for mortality risk according to cardiovascular disease status
Fitness categories 
according to peak 
METs achieved
No CVD (n = 6,167) CVD (n = 4,035)
No. of deaths (%) Hazard ratio (95% CI) P value Hazard ratio (95% CI) No. of deaths (%) P value
≤5 MET 564 (42.8)   1.00 (referent) —   1.00 (referent) 799 (58.9) —
5.1–6.5 MET 351 (23.9) 0.67 (0.59–0.77) <0.001 0.77 (0.69–0.87) 449 (43.9) <0.01
6.6–8.4 MET 362 (16.4.0) 0.54 (0.47–0.62) <0.001 0.57 (0.49–0.65) 322 (28.5) <0.01
≥8.5 MET 72 (6.1) 0.26 (0.20–0.34) <0.001 0.36 (0.28–0.46) 72 (13.7) <0.01
Abbreviations: CI, confidence interval; MET, metabolic equivalent; MWD, muscle-wasting disease.
The model was adjusted for age, resting blood pressure, body mass index, ethnicity, beta-blockers, calcium channel blockers, angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, antiarrhythmic agents, insulin, oral hypoglycemic agents, history of 
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capacity among individuals on stain therapy was signifi-
cantly higher than that among those not treated with statins 
in this study (Table  1). Significantly lower systolic BP and 
diastolic BP were also observed in those treated with statins. 
This is in accord with previous findings suggesting a modest 
BP-lowering effect of statins.5,9–11
Our cohort is unique. Veterans have equal access to care 
independent of a patient’s financial status provided by the 
Veterans Health Administration. This permits epidemio-
logic evaluations while minimizing the influence of dis-
parities in medical care.31,32 This, along with the existence 
of electronic health records within the Veterans Affairs 
Healthcare System, enables detailed observation of prior 
history and alterations in health status. Because mortality 
rates in individuals with MWD were significantly higher vs. 
the rest of the cohort (47.5% vs. 25.9%) and exercise capac-
ity was lower (6.7 ± 2.0 vs. 6.2 ± 1.8 METs; P < 0.001), Cox 
proportional hazard models were constructed with these 
individuals included and excluded from the analyses. The 
models did not change substantially. This, along with the 
exclusion of those with an exercise capacity <2 METs, lowers 
the likelihood of reverse causality and supports the validity 
of the fitness–statin therapy and mortality risk association in 
hypertensive individuals.
This study has several limitations because of its design. 
We only had information on all-cause mortality and did not 
have data on cardiovascular interventions or cardiovascular 
mortality. Our cohort was comprised of male veterans only, 
which limits the ability to generalize the findings to women. 
Fitness levels were based on 1 assessment, and follow-up data 
on the fitness status of the participants were not available. 
The 2 different exercise protocols used to assess fitness is 
also a potential limitation. Our previous work suggests that 
the ramp protocol is somewhat more accurate in predicting 
measured METs.15,33 However, separate analyses from the 2 
locations yielded similar results, suggesting that the differ-
ences in protocols had minimal impact.
We have no data regarding adverse effects of statins to 
discern whether statin therapy may have influenced exer-
cise capacity. In this regard, the use of satins was progres-
sively higher with higher fitness (least-fit group  =  34.5%; 
fit froup  =  46%; moderate-fit group  =  45.2%; and high-fit 
group = 55.8%). Finally, the onset of chronic diseases, their 
severity, and duration of therapy were not evaluated, and 
dietary information was not available in our records.
Our findings support the concept that both statin therapy 
and higher fitness are effective in lowering premature all-
cause mortality in hypertensive individuals. The combina-
tion of the 2 was more efficacious in lowering mortality in 
hypertensive individuals than either alone. Thus, despite 
reports of muscle damage and impaired cardiorespiratory 
fitness as a result of statin therapy, our findings suggest that 
the 2 therapeutic strategies can be used effectively in lower-
ing mortality risk for hypertensive individuals.
Interestingly, a modest increase in fitness status alone (5.1–
8.4 METs) was associated with a 24%–40% lower mortality 
risk, similar to the 25% lower risk observed with statin ther-
apy alone (least fit/statins; Table 4; Figure 2). Furthermore, 
mortality risk was significantly lower among individuals in 
the highest fitness categories (exercise capacity ≥ 8.5 METs) 
not treated with statins compared with the least-fit group on 
statin therapy (Figure 2). This suggests that if statin therapy 
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is not an option, higher fitness provides protection that is 
similar or even greater than that achieved by statin therapy 
in unfit individuals. The exercise capacity necessary to real-
ize these health benefits (>5 METs) is achievable by many 
middle-aged and older adults by daily exercise such as brisk 
walking.16 Thus, improved fitness may provide an attractive 
adjunct therapy to statins and even an alternative when sta-
tin therapy cannot be prescribed.
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